Abstract
The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aged
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20 / immunology
-
Antigens, Neoplasm / immunology
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / immunology
-
Brain Neoplasms / therapy
-
Central Nervous System Neoplasms / drug therapy
-
Central Nervous System Neoplasms / immunology
-
Central Nervous System Neoplasms / therapy*
-
Cohort Studies
-
Combined Modality Therapy
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / therapeutic use*
-
Disease-Free Survival
-
Drug Evaluation
-
Drug Resistance, Neoplasm
-
Eye Neoplasms / drug therapy
-
Eye Neoplasms / immunology
-
Eye Neoplasms / therapy
-
Female
-
Humans
-
Immunotherapy*
-
Life Tables
-
Lymphoma, B-Cell / drug therapy
-
Lymphoma, B-Cell / immunology
-
Lymphoma, B-Cell / therapy*
-
Male
-
Methotrexate / pharmacology
-
Methotrexate / therapeutic use
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / therapy
-
Remission Induction
-
Retrospective Studies
-
Rituximab
-
Salvage Therapy*
-
Survival Analysis
-
Temozolomide
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Antigens, Neoplasm
-
Antineoplastic Agents, Alkylating
-
Rituximab
-
Dacarbazine
-
Temozolomide
-
Methotrexate